European medicines agency confirms acceptance of marketing application for avt06, a proposed biosimilar to eylea® (aflibercept)

Reykjavik, iceland and london, aug. 15, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma, a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the european medicines agency (ema) has accepted a marketing authorization application for avt06, alvotech's proposed biosimilar to eylea® (aflibercept). the process to obtain marketing authorization could be completed in the third quarter of 2025.
ALVO Ratings Summary
ALVO Quant Ranking